DeepMed Research

Population Health Research Institute

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Established: 1999-01-01

Employees: 251

Market Cap: -

Website: http://www.phri.ca

Clinical Trials

Aldosterone BloCkade for Health Improvement EValuation in End-stage Renal Disease

Phase 3

Completed

Conditions: Endstage Renal Disease

Interventions: Drug: Placebo Oral Tablet
Drug: Spironolactone 25Mg Tablet

First Posted Date: 2017-01-13

Last Posted Date: 2025-03-20

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 2538

Registration Number: NCT03020303

Locations: 🇬🇧
City Hospital, Nottingham, United Kingdom
🇬🇧
Salford Royal Hospital, Salford, United Kingdom
🇨🇳
Tianjin Fifth Central Hospital, Tianjin, China

and more 138 locations

NOACs for Stroke Prevention in Patients With Atrial Fibrillation and Previous ICH

Phase 2

Completed

Conditions: Atrial Fibrillation
Intracerebral Hemorrhage

Interventions: Drug: NOAC
Drug: Acetylsalicylic Acid

First Posted Date: 2016-12-21

Last Posted Date: 2020-03-20

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 30

Registration Number: NCT02998905

Locations: 🇨🇦
Foothills Medical Centre, Calgary, Alberta, Canada
🇨🇦
University of Alberta Hospital, Edmonton, Alberta, Canada
🇨🇦
Vancouver Coastal Health Research Institute, Vancouver, British Columbia, Canada

and more 6 locations

Tetralogy of Fallot for Life

Completed

Conditions: Congenital Heart Disease
Tetralogy of Fallot
Congenital Heart Defect

First Posted Date: 2016-11-18

Last Posted Date: 2022-12-21

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 1108

Registration Number: NCT02968264

Locations: 🇺🇦
Children's Cardiac Center - Ukraine, Kyiv, Ukraine
🇳🇵
Manmohan Cardiothoracic Vascular and Transplant Center, Kathmandu, Nepal
🇸🇦
King Abdulaziz University Hospital, Jeddah, Makkah, Saudi Arabia

and more 17 locations

Preventing pAIn With NMDA Antagonists - Steroids in Thoracoscopic lObectomy Procedures (PAIN-STOP) Pilot Trial

Phase 3

Terminated

Conditions: Pain, Postoperative

Interventions: Drug: Steroid active
Drug: NMDA active
Drug: Steroid placebo
Drug: NMDA placebo

First Posted Date: 2016-11-01

Last Posted Date: 2020-01-18

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 27

Registration Number: NCT02950233

Locations: 🇨🇦
St. Joseph's Healthcare, Hamilton, Ontario, Canada
🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States

Safety of Continuing CHemotherapy in Overt Left Ventricular Dysfunction Using Antibodies to HER-2

Phase 1

Completed

Conditions: Heart Failure
Breast Cancer

Interventions: Drug: standard-of-care treatments for LV impairment

First Posted Date: 2016-09-20

Last Posted Date: 2020-10-09

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 20

Registration Number: NCT02907021

Locations: 🇨🇦
Juravinski Hospital, Hamilton, Ontario, Canada

The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial

Phase 4

Withdrawn

Conditions: Chronic Kidney Disease
Cerebrovascular Stroke
Acute Bleeding

Interventions: Drug: Continued therapy with the prescribed oral anticoagulant
Device: Watchman

First Posted Date: 2016-08-31

Last Posted Date: 2018-03-29

Lead Sponsor: Population Health Research Institute

Registration Number: NCT02885545

Locations: 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada

Avoid Transvenous Leads in Appropriate Subjects

Not Applicable

Completed

Conditions: Ventricular Arrhythmia

Interventions: Device: Implantable Cardioverter Defibrillator

First Posted Date: 2016-08-26

Last Posted Date: 2022-05-31

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 544

Registration Number: NCT02881255

Locations: 🇨🇦
Victoria Cardiac Arrhythmia Trials Inc., Victoria, British Columbia, Canada
🇨🇦
St. Paul's Hospital, Vancouver, British Columbia, Canada
🇨🇦
Southlake Regional Health Centre, Newmarket, Ontario, Canada

and more 11 locations

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Superiority

Phase 3

Withdrawn

Conditions: Rheumatic Heart Disease

Interventions: Drug: Rivaroxaban (15 mg)
Drug: Aspirin

First Posted Date: 2016-07-14

Last Posted Date: 2022-07-19

Lead Sponsor: Population Health Research Institute

Registration Number: NCT02832531

INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority

Phase 3

Completed

Conditions: Rheumatic Heart Disease

Interventions: Drug: Rivaroxaban (20 mg)
Drug: Vitamin K antagonists (VKA)

First Posted Date: 2016-07-14

Last Posted Date: 2022-10-05

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 4565

Registration Number: NCT02832544

Locations: 🇪🇬
Beni Suef University Hospital, Banī Suwayf, Egypt
🇪🇬
Zagazig University Hospital, Zagazig, Egypt
🇮🇳
King George's Medical College, Lucknow, Uttar Pradesh, India

and more 136 locations

Remission Evaluation of a Metabolic Intervention in Type 2 Diabetes With Sitagliptin (REMIT-Sita)

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: insulin glargine
Drug: sitagliptin/metformin
Behavioral: lifestyle therapy

First Posted Date: 2015-12-08

Last Posted Date: 2022-03-25

Lead Sponsor: Population Health Research Institute

Target Recruit Count: 102

Registration Number: NCT02623998

Locations: 🇨🇦
University of Calgary, Calgary, Alberta, Canada
🇨🇦
LMC, Markham, Ontario, Canada
🇨🇦
Univeristy of Montreal, Montreal, Quebec, Canada

and more 3 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy